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Abstract
Background In autologous chondrocyte implantation
(ACI), the periosteum patch which is sutured over the carti-
lage defect has been identiWed as a major source of compli-
cations such as periosteal hypertrophy. In the present
retrospective study, we compared midterm results of Wrst-
generation ACI with a periosteal patch to second generation
ACI using a biodegradable collagen Xeece (BioSeed-C) in
82 patients suVering from chronic posttraumatic and degen-
erative cartilage lesions of the knee.
Methods Clinical outcome was assessed in 42 patients of
group 1 and in 40 patients of group 2 before implantation of
the autologous chondrocytes and at a minimum follow-up
of 2 years using the ICRS score, the modiWed Cincinnati
score and the Lysholm score.
Results Although patients treated with BioSeed-C had
more previous surgical procedures on their respective
knees, highly signiWcant improvements (P < 0.001) were
assessed in both groups at comparable outcome levels: the
ICRS score improved from grade D (poor) preoperatively
to grade C (fair); the modiWed Cincinnati knee score from
3.26 to 6.4 (group 1) and 3.3 and 6.88 (group 2). Lysholm
score improved from 33 to 70 points (group 1) and from 47
to 78 points (group 2), respectively. Revision surgery was
due to symptomatic periosteal hypertrophy (n = 4), graft
failure (n = 3), plica syndrome (n = 2) synovectomy (n = 1)
(group 1); and graft failure (n = 2), debridement (n = 1),
synovectomy (n = 2) (group 2).
Conclusion These results suggest that BioSeed-C is an
equally eVective treatment option for focal degenerative
chondral lesions of the knee in this challenging and com-
plex patient proWle.
Keywords Knee · Cartilage · Biosurgery · Trauma · 
Degenerative defects
Introduction
The treatment of cartilage defects represents a common,
complex and multifaceted task for orthopaedic surgeons;
particularly, in young patients suVering from large carti-
lage defects, there are only limited conservative and sur-
gical treatment options. Thus, several eVorts to restore
articular cartilage were undertaken [4, 11, 14, 20, 23,
38]. However, these cartilage repair techniques provide
only limited durability of the repair tissue [29] or
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958 Arch Orthop Trauma Surg (2010) 130:957–964suitable for small defects only [6]. In contrast, autolo-
gous chondrocyte implantation (ACI) introduced in
1994, lacks these disadvantages, but provides hyaline-
like cartilage [4, 35–37].
Autologous chondrocyte implantation has been recom-
mended as the treatment of choice for symptomatic carti-
lage defects larger than 2 cm [2] and for failed cartilage
repair procedures and more than 10,000 patients worldwide
have been treated with ACI already [26]. Encouraging short
to midterm results of ACI were reported from case series
[7, 9, 24, 25, 33, 39], while randomised clinical trials could
not clearly demonstrate superiority of ACI compared with
either microfracture or osteochondral cylinder transplanta-
tion [3, 12, 13, 17, 18]. First-generation ACI involves har-
vesting a periosteal Xap from the tibia that later has to be
Wxed to the surrounding cartilage requiring a contained car-
tilage lesion. Application in some regions of the knee may
thus be delicate or even impossible. Notably, the periosteal
Xap covering the defect has been identiWed as a potential
source of complications resulting in reoperations in up to
25% of the patients [19, 24, 27, 28, 37]. To eliminate this
signiWcant disadvantage, to prevent chondrocytes from
dediVerentiation, to improve adhesion and to facilitate
handling, ACI has been reWned through the development of
bioresorbable matrices (e.g., MACI, BioSeed-C). With
these grafts, it is no longer necessary to have a stable carti-
lage rim surrounding the defect and non-contained lesions
can be addressed as well as contained lesions. Addressing
defects on the medial or lateral femoral condyle that are
smaller than 2 cm [2], BioSeed-C can be implanted arthro-
scopically [8].
BioSeed-C is now frequently applied to a signiWcant
patient population. Theoretically, the advantages of this
technique would make it a better choice for the treatment of
full-thickness cartilage lesions of the knee outclassing stan-
dard periosteum ACI. However, no study has compared
BioSeed-C to the standard method of periosteum ACI yet.
Therefore, orthopaedic surgeons cannot be sure of whether
they deprive their patients of a potentially better articular
cartilage repair if keeping at periosteum ACI. To determine
which of the two techniques should be chosen to ensure
best treatment results, to optimise the outcome and the ben-
eWt for the patients suVering from full-thickness cartilage
lesions of the knee and to assess typical complications of
both techniques, we performed a retrospective study to
evaluate and to compare the clinical outcomes of standard
ACI to ACI using a biodegradable polymer-Xeece.
Materials and methods
In this clinical non-randomised retrospective study,
82 patients (42 women, 40 men) meeting the following
criteria were included: (1) clinical and radiographic [16] focal
full-thickness cartilage lesions of the knee on the medial
or lateral femoral condyle, patella or trochlea; (2) lesion
grades III–IV in the Outerbridge classiWcation [34]; (3)
symptom-like pain or dysfunction of the knee joint and
(4) given patient’s oral consent following adequate infor-
mation about mode of data acquisition, processing, analy-
sis, interpretation and publication, according to regional
guidelines.
Patients fulWlling at least one of the following criteria
were not included in this study: (1) severe osteoarthritis; (2)
diVuse tricompartmental degeneration; (3) multiple small
lesions <1 cm [2]; (4) bilateral chondrocyte implantation;
(5) age over 65 years; (6) presence of active infection; (7)
injuries or aZictions of regions other than the knee; (8)
gravity; (9) neoplasms; (10) radicular pain; (11) paralysis;
(12) psychiatric diseases and (13) Wbromyalgia.
Between March 1997 and October 2004, 82 patients
were treated with ACI for full-thickness cartilage lesions of
the knee in one hospital. They formed two groups: group 1
was treated with standard periosteum ACI and group 2 with
ACI using a biodegradable Xeece (BioSeed-C). There were
29 men and 13 women in group 1 and 22 men and 18
women in group 2. Mean defect size was 6.38 cm² (2–17.5)
in group 1 and 4.6 cm² (2–15) in group 2 (P < 0.001). Aver-
age age was 34 (16–53) and 36 years (17–64), respectively.
In both groups, defects were mainly situated on the medial
femoral condyle (group 1: n = 29, group 2: n = 27). Mean
follow-up of the periosteum ACI group was 36 months
(24–63), of the BioSeed-C group 24 months (24 months).
All but three patients of group 1 had at least one previous
surgical procedure on the knee, with a mean of 1.94 (0–4).
In group 2, all patients had previous surgical procedures of
the knee with a mean of 3.35 (1–11), including meniscecto-
mies (group 1: n = 20, group 2: n = 20), reconstructions of
the anterior cruciate ligament (group 1: n = 10, group 2:
n = 12) and cartilage repair procedures like abrasion arthro-
plasty (group 1: n = 10, group 2: n = 0), microfractures and
drillings (group 1: n = 17, group 2: n = 13), respectively. In
patients with the disruption of the anterior cruciate liga-
ment, ACL reconstruction is required and was performed
together with ACI; so was done with malalignment. More
detailed information about the study cohorts is given in
Table 1.
ICRS score [15], Lysholm score [21], Cincinnati
score [31, 32] and the modiWed Cincinnati knee score
[30] were used for evaluation of outcome. Data acquisi-
tion was performed by an independent investigator.
Clinical evaluation and scoring were done preopera-
tively and at follow-up. To calculate levels of signiW-
cance, the paired and unpaired Wilcoxon-rank sum test
was done with SPSS for Windows Version 11.0 (SPSS,
Chicago, IL, USA).123
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960 Arch Orthop Trauma Surg (2010) 130:957–964Surgical technique
For both procedures, periosteum ACI and BioSeed-C, the
cartilage defect was assessed arthroscopically for deWnite
indication to ACI. Approximately, 250 mg of articular car-
tilage was taken as a biopsy from a lesser or non-weight
bearing region of the knee as the linea terminalis or the
intercondylar notch. The biopsy was placed in transport
container provided by the commercial cell culturing com-
pany and sent to the respective company’s cell culturing
facility (Genzyme Biosurgery, Cambridge, MA, USA;
Biotissue Technologies, Freiburg, Germany). There, chon-
drocytes were expanded in vitro. For conventional ACI,
these chondrocytes were brought into a suspension at for
later injection. For BioSeed-C, the chondrocytes were rear-
ranged three dimensionally in Wbrin and a polymer-based
scaVold of polyglycolic/polylactic acid (polyglactin, vicryl)
and polydioxanone.
The implantation of the cultured autologous chondrocytes
was performed at a date according to the laboratory guide-
lines. Under general or local anaesthesia and antibiotic
prophylaxis, a medial or lateral arthrotomy was performed
preparing the cartilage defect in a tourniquet-controlled
bloodless Weld. The cartilage lesion was carefully debrided
back to healthy cartilage building a stable rim.
For periosteum ACI, a template was Wtted to defect size
and periosteum was harvested from the lateral aspect of the
tibia using this template. This periosteal Xap was Wtted to
defect size and sutured into the defect cambium layer down
(Vicryl 6-0) leaving a gap for the injection of the cultured
chondrocytes (Fig. 1 b, arrowhead). The rim was sealed
with Wbrin glue. The chondrocyte suspension was injected
under the periosteal Xap and the Xap was Wnally secured
and sealed with Wbrin glue and a Wnal suture.
BioSeed-C is a resorbable composite material consisting
of polyglaction 910 and poly-p-dioxanone collagen Xeece
seeded with autologous chondrocytes in a three-dimen-
sional matrix. It contains 20 £ 106 cells/cm3 Wxed with
approximately 5–7 mg Wbrin adhesive and will be resorbed
after 2–3 months. For the BioSeed-C procedure, the defect
was debrided to a rectangular shape down to the subchon-
dral bone using a sharp curette (Fig. 2d). A template was
taken and the Xeece Wtted to size. Using a resorbable thread,
the graft (Fig. 2a) was armed with a double-knot loop at
each corner (Vicryl 2-0). One threefold knot approximately
1 cm from the edge secures the sling (Fig. 2b). An addi-
tional knot approximately 1 cm out moors the sling and
serves as a pulley. Using k-wires (1.7 mm, 35 cm long with
eye), four drill holes on the corners of the defect were made
to Wx the implant transosseously (Fig. 2c). Firm action on
the pulleys guided the knots into the transosseous drill
holes at the corners of the defect (Fig. 2d). The pulley
slings were cut close to their dermal exit (Fig. 2e).
For both procedures, arthrotomy was closed under care-
ful haemostasis. For postoperative management, continu-
ous passive motion machines were used starting the Wrst
postoperative day. Range of motion initially was limited to
40° of Xexion and was increased in stages of 5°–10° per
day limited to 90° of Xexion. The operated knee was
unloaded for 6 weeks with approximately 15% of the body
weight. Physiotherapy was prescribed individually. Starting
the seventh postoperative week, load was increased gradu-
ally and speciWc isometric strengthening exercises were
performed. Light exercise such as walking or cycling was
Fig. 1 Periosteum ACI: the 
cartilage defect was debrided 
back to healthy cartilage (left). 
A periost patch harvested from 
the tibia was sutured into the 
defect cambium layer down. On 
the upper left side, one suture 
was skipped (arrow) which will 
be done later to allow injection 
of the autologous chondrocyte 
suspension (right)123
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contact sports was not recommended before 12 months
postoperatively.
Results
Intraoperatively, no loosening, ablation or derangement of
either transplant occurred. No knee joint infection and no
allergic reaction occurred in either group. Postoperatively,
neither an extension lag nor a Xexion deWcit could be
observed. One patient of the BioSeed-C group had a mod-
erate eVusion at follow-up, but not other problems and did
well later on. The rate of follow-up in the periosteum group
was 100%. In the BioSeed-C group, the grafts of one patient
were removed in a peripheral institution due to soft regenera-
tion tissue after 9 months. This patient was registered as a
treatment failure. Another patient developed paraplegia dur-
ing follow-up and, therefore, was excluded from the study.
One patient was lost to follow-up due to unknown address.
At follow-up, mean scores signiWcantly increased in
both groups compared with baseline: in the periosteal
group, the ICRS score improved from grade D (poor) pre-
operatively to grade C (fair) post-op (P < 0.0001) with a
range from grade A (excellent) to grade D (poor) (Fig. 3a).
The modiWed Cincinnati knee score improved from 3.26 to
6.44 (patient) (P < 0.0001) and from 3.36 to 6.88 (physi-
cian) (P < 0.0001) (Fig. 3b, c). Mean Lysholm score
improved from 33 to 70 points (P < 0.0001) (Fig. 3d).
In BioSeed-C group, like in the periosteum group, the
ICRS score improved from grades D to C as well
(P < 0.0001) (Fig. 3a). The modiWed Cincinnati knee score
increased from 3.3 to 6.4 (patient) (P < 0.0001) and from
4.9 to 6.5 (physician) (P < 0.0001) (Fig. 3b, c). Mean Lys-
holm score enhanced from 47 to 78 points (P < 0.0001)
(Fig. 3d). There was no signiWcant diVerence between
groups 1 and 2 in the ICRS score rating (P = 1) and in the
Lysholm score (P = 0.065). In the overall rating of the
modiWed Cincinnati knee score (patient), the diVerence
between groups was not statistically signiWcant (P = 0.39).
However, the physician rating was signiWcantly better in
the periosteum group (P = 0.033).
In the periosteum group, 10 patients required revision
surgery, due to symptomatic periosteal hypertrophy (n = 4)
or graft failure (n = 3), plica syndrome (n = 2) and synovec-
tomy (n = 1).
In the BioSeed-C group, reoperations were necessary
and regarded as directly related to ACI in Wve patients. One
patient underwent graft removal in a peripheral institution
and was thus registered as a treatment failure. Two patients
had a synovectomy and one patient had a debridement and
one a total knee replacement, respectively.
Discussion
The aim of the present study was to compare the clinical
outcome of standard periosteum ACI to BioSeed-C (ACI
using a biodegradable Xeece) in patients with focal
degenerative cartilage defects of the knee. Patients of both
treatment groups showed highly signiWcant increases in
the respective scores used for outcome measurement
Fig. 2 BioSeed-C is delivered 
as a 20 £ 30 £ 2 mm polymer-
Xeece seeded with 2 £ 106 
autologous chondrocytes (a). 
The graft is armed with vicryl 
sutures at every corner which 
serve as a pulley (b) and are 
Wxed transosseously using 
1.7-mm-k-wires in an insideout 
technique (c); that way, the graft 
is smoothly Wtted into the defect 
(d) and securely Wxed 
in a press-Wt technique (e)123
962 Arch Orthop Trauma Surg (2010) 130:957–964demonstrating major improvements in activities of daily
living, ability to work and in sports. Patients treated with
periosteal ACI required twice as many reoperations
as patients treated with BioSeed-C. In the ICRS score,
the patient rating of the modiWed Cincinnati knee score
and the Lysholm score, the outcome was comparable between
the periosteum and the BioSeed-C group. However, in
the objective and strict ICRS score and in the patient
rating of the modiWed Cincinnati knee score, patients treated
with periosteum ACI scored slightly, but not signiWcantly
better, whereas in the Lysholm score, it was vice versa.
In contrast, in the physician’s rating, BioSeed-C patients
scored slightly worse than periosteum patients, because of
better baseline ratings.
The patients of the two groups compared in this study
diVered in defect size, number of previous or concomitant
surgical procedures and length of the postoperative follow-
up period. This may inXuence the results. However, the
impact of this potential eVect is unknown. The group
treated with conventional ACI had larger defects and longer
follow-up. However, a direct comparison of the two groups
may be inappropriate, as there were signiWcantly more pre-
vious surgical procedures in the group treated with Bio-
Seed-C.
When compared with case series, randomised studies
evaluating ACI versus other cartilage repair surgeries as
reported previously are favourable [3, 12, 13, 17, 18]. A
recent systematic review comparing ACI and osteochondral
autograft transfer with each other with one another and with
traditional abrasive techniques demonstrated no clear supe-
riority of ACI over microfracture [22] in line with the Wnd-
ings published by other authors [17, 18]. However, in
another study, ACI showed a superior cartilage regenerate
than microfracture at same clinical short-term results [39].
When comparing the two ACI methods, the present
study shows that these are equally eVective. Advantages
of the BioSeed-C techniques comprise less morbidity, as
no periosteum has to be harvested and the option of arth-
roscopical implantation. Defects of the femoral condyles
can be addressed arthroscopically depending on lesion
size and location which is associated with faster recov-
ery after surgery and with better cosmetical results. Fur-
ther advantages of BioSeed-C, are that it is easier to
apply, is more stable than the periosteum cartilage trans-
plant and triggers less second look surgeries, because
there can be no periosteum hypertrophy. This may partly
be due to the lacking periosteum hypertrophies fre-
quently causing reoperations in patients treated with ACI
using periosteum. ACI involves an open technique with
inherent disadvantages such as adhesions and prolonged
recovery. Therefore, an arthroscopical approach to ACI
as published previously is desirable and could poten-
tially reduce postoperative morbidity [8]. The authors
believe that this is the Wrst study comparing standard
ACI to a 3D Xeece technique (BioSeed-C), representing
a non-randomised retrospective, comparative study with
at least 40 patients in each group. However, the outcome
of this study should be interpreted with care and statisti-
cal eVects associated with small numbers of patients may
be considered.
First-generation tissue engineering grafts such as perios-
teum ACI have been demonstrated to be an appropriate
therapy for the regeneration of posttraumatic defects
[5, 10]. However, second generation cartilage tissue
Fig. 3 Clinical outcome after 
2 years as measured by the 
ICRS, modiWed Cincinnati knee 
score and the Lysholm score. All 
scores showed highly signiWcant 
(P < 0.0001) improvements at 
follow-up. The ICRS score 
improved from grade IV at 
baseline to grade III at follow-up 
(a). The modiWed Cincinnati 
knee score as evaluated by 
patient (b) and physician 
(c) showed highly signiWcant 
improvements in the evaluated 
follow-up period. The Lysholm 
score improved highly 
signiWcant as well (d)
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considered to be technically more attractive. For instance,
in a series of 47 cartilage defects, similar outcomes were
obtained clinically as well as histologically [1]. In a multi-
center study evaluating Hyalograft C, which consists of
autologous chondrocytes embedded in a derivative of hyal-
uronic acid, more than 90% of patients showed improve-
ments of the ICRS score [23]. Clinical assessment as done
by the Meyers score, the Lysholm score and in the ICRS
scores was improved in a prospective study investigating
5-year results of matrix associated ACI [2].
In summary, we regard the outcome of this study as a
decent treatment result for this diYcult and highly demand-
ing patient proWle, particularly because patients treated with
BioSeed-C had the same outcome levels, e.g., in knee-
related performance and quality of life as the patients
treated with periosteum ACI, although they have had more
surgeries on their knees before.
Concerning its advantages in comparison to periosteum
ACI, we conclude that BioSeed-C is equally eVective as
periosteum ACI.
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signed any agreementwith a commercial interest related to this study
which would in any way limit publicationof any and all data generated
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